At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 676 enrolled
Drug / intervention
MK3207- 2.5 mg +6 moredrug
Likely dose
MK3207- 2.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IIb, Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-finding Study of MK3207 in the Treatment of Acute Migraine
In Brief
A Phase 2 clinical trial evaluating MK3207- 2.5 mg, MK3207- 5 mg, and 5 other interventions for Migraine. Completed, enrolled 676 participants.
Detailed Summary
The purpose of the study is to demonstrate the effectiveness and appropriate dosage level of MK3207 in the treatment of acute migraine.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2008
First PostedJul 2008
Primary CompletionJan 2009
TodayJul 2026
First PostedJul 10, 2008
Enrollment StartJul 1, 2008
Primary CompletionJan 1, 2009
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 18.0 years ago
Interventions
MK3207- 2.5 mgdrug
Arm 1: MK3207 2.5 mg taken after migraine onset.
MK3207- 5 mgdrug
Arm 2: MK3207 5 mg taken after migraine onset.
MK3207- 10 mgdrug
Arm 3: MK3207 10 mg taken after migraine onset.
MK3207- 20 mgdrug
Arm 4: MK3207 20 mg taken after migraine onset.
MK3207- 50 mgdrug
Arm 5: MK3207 50 mg taken after migraine onset.
MK3207- 100 mgdrug
Arm 6: MK3207 100 mg taken after migraine onset.
Comparator: placebo (unspecified)drug
Placebo taken after migraine onset.